CBD Nanoemulsion Protected Against Parkinson's-Like Brain Damage in Rats
A CBD nanoemulsion formulation normalized markers of inflammation, oxidative stress, and abnormal protein aggregation in both the brain and gut of rats with chemically induced Parkinson's-like disease.
Quick Facts
What This Study Found
CBD nanoemulsion treatment restored glutathione levels (which had dropped 38-47% from rotenone treatment), reduced alpha-synuclein accumulation in both the striatum and duodenum, and normalized glial activation markers GFAP and IBA1 to control levels.
Key Numbers
Rotenone caused 38-47% reduction in glutathione across brain regions (worst in striatum). CBD nanoemulsion at all three doses restored glutathione to control levels. Alpha-synuclein accumulation was reduced in both striatum and duodenum. Six experimental groups with behavioral and biochemical outcomes measured.
How They Did This
Wistar rats were divided into six groups receiving combinations of rotenone (Parkinson's model) and three doses of CBD nanoemulsion (1.25, 2.5, 5.0 mg/kg). Behavioral testing (open field, Y maze, novel object recognition) and biochemical, histological, and immunohistochemical analyses assessed outcomes in brain regions and duodenum.
Why This Research Matters
Parkinson's disease often starts with gut symptoms before motor problems appear. This study is notable for examining CBD's effects in both the brain and the intestine simultaneously, reflecting the growing understanding that Parkinson's pathology involves the gut-brain axis.
The Bigger Picture
The gut-brain connection in Parkinson's is increasingly recognized, with alpha-synuclein pathology potentially spreading from the gut to the brain. CBD's ability to address pathology in both locations in this animal model aligns with the need for treatments that target this dual-site disease process.
What This Study Doesn't Tell Us
Rat model of Parkinson's induced by chemical toxin does not fully replicate human disease. Nanoemulsion formulation may behave differently in humans. Short-term study does not assess whether protection persists. Multiple brain regions and outcome measures increase the chance of false positives.
Questions This Raises
- ?Whether the gut-protective effects of CBD could slow the progression of early-stage Parkinson's pathology in humans
- ?How the nanoemulsion formulation compares to standard CBD oil in delivering neuroprotective effects
Trust & Context
- Key Stat:
- Evidence Grade:
- Well-designed preclinical study with multiple doses and comprehensive outcome measures, but animal model results require human validation.
- Study Age:
- Published 2025.
- Original Title:
- Neuroprotective effects of a cannabidiol nanoemulsion in a rotenone-induced rat model of Parkinson's disease: Insights into the gut-brain axis.
- Published In:
- European journal of pharmacology, 1002, 177748 (2025)
- Authors:
- Santos, Júlio César Claudino Dos, Aquino, Pedro Everson Alexandre de, Rebouças, Conceição da Silva Martins, Sallem, Camilla Costa, Guizardi, Marissa Prudente Pinheiro, Noleto, Felipe Micelli, Zampieri, Davila de Sousa, Ricardo, Nágila Maria Pontes Silva, Brito, Débora Hellen Almeida de, Silveira, Edilberto Rocha, Leitão, Renata Ferreira de Carvalho, Brito, Gerly Anne de Castro, Viana, Glauce Socorro de Barros
- Database ID:
- RTHC-07572
Evidence Hierarchy
Frequently Asked Questions
Why use a nanoemulsion instead of regular CBD oil?
Nanoemulsions create extremely small CBD droplets that can be absorbed more efficiently by the body. This could mean lower doses are needed to achieve therapeutic effects compared to standard oral CBD.
Why did they look at the gut in a Parkinson's study?
Growing evidence suggests Parkinson's disease pathology may start in the gut and spread to the brain via the vagus nerve. Many Parkinson's patients experience digestive symptoms years before motor problems appear.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- sublingual-vs-oral-vs-inhaled-thc-absorption
Cite This Study
https://rethinkthc.com/research/RTHC-07572APA
Santos, Júlio César Claudino Dos; Aquino, Pedro Everson Alexandre de; Rebouças, Conceição da Silva Martins; Sallem, Camilla Costa; Guizardi, Marissa Prudente Pinheiro; Noleto, Felipe Micelli; Zampieri, Davila de Sousa; Ricardo, Nágila Maria Pontes Silva; Brito, Débora Hellen Almeida de; Silveira, Edilberto Rocha; Leitão, Renata Ferreira de Carvalho; Brito, Gerly Anne de Castro; Viana, Glauce Socorro de Barros. (2025). Neuroprotective effects of a cannabidiol nanoemulsion in a rotenone-induced rat model of Parkinson's disease: Insights into the gut-brain axis.. European journal of pharmacology, 1002, 177748. https://doi.org/10.1016/j.ejphar.2025.177748
MLA
Santos, Júlio César Claudino Dos, et al. "Neuroprotective effects of a cannabidiol nanoemulsion in a rotenone-induced rat model of Parkinson's disease: Insights into the gut-brain axis.." European journal of pharmacology, 2025. https://doi.org/10.1016/j.ejphar.2025.177748
RethinkTHC
RethinkTHC Research Database. "Neuroprotective effects of a cannabidiol nanoemulsion in a r..." RTHC-07572. Retrieved from https://rethinkthc.com/research/santos-2025-neuroprotective-effects-of-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.